Literature DB >> 6525331

Visual motor co-ordination and dynamic visual acuity.

R G Borland, A N Nicholson.   

Abstract

Data on the effect of an antihistamine (triprolidine 10 mg) on visuo-motor coordination and dynamic visual acuity were used to establish interactions between these skills. Analysis of covariance and principal component analysis were used. The analyses suggested two main effects--an effect on the activity of the neuromuscular system and one which impaired ability to anticipate target movement. Detection of impaired performance by any task may have wider implications to the effectiveness of the individual than that obviously suggested by the skill itself.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6525331      PMCID: PMC1463351          DOI: 10.1111/j.1365-2125.1984.tb02583.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Performance studies with antihistamines.

Authors:  C H Clarke; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1978-07       Impact factor: 4.335

2.  The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration.

Authors:  P R Bittencourt; P Wade; A T Smith; A Richens
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

3.  Performance studies with diazepam and its hydroxylated metabolites.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Comparison of the residual effects of two benzodiazepines (nitrazepam and flurazepam hydrochloride) and pentobarbitone sodium on human performance.

Authors:  R G Borland; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

5.  The H2-antagonists, cimetidine and ranitidine: studies on performance.

Authors:  A N Nicholson; B M Stone
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  The H1-antagonist mequitazine: studies on performance and visual function.

Authors:  A N Nicholson; B M Stone
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Benzodiazepines impair smooth pursuit eye movements.

Authors:  P R Bittencourt; P Wade; A T Smith; A Richens
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

8.  Psychomotor performance and real driving performance of outpatients receiving diazepam.

Authors:  J J de Gier; B J 't Hart; F A Nelemans; H Bergman
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Effect of the antihistamines, brompheniramine maleate and triprolidine hydrochloride, on performance in man.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

  9 in total
  28 in total

1.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

2.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Authors:  J P van der Post; S J de Visser; M L de Kam; M Woelfler; D C Hilt; J Vornov; E S Burak; E Bortey; B S Slusher; T Limsakun; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

3.  Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.

Authors:  Remco W M Zoethout; Rik C Schoemaker; Lineke Zuurman; Hans van Pelt; Albert Dahan; Adam F Cohen; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

4.  Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

Authors:  Marieke Liem-Moolenaar; Mandana Rad; Stefano Zamuner; Adam F Cohen; Francesca Lemme; Kari L Franson; Joop M A van Gerven; Emilio Merlo Pich
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

5.  Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Authors:  Anne C Baakman; Rob Zuiker; Joop M A van Gerven; Nicholas Gross; Ronghua Yang; Michael Fetell; Ari Gershon; Yossi Gilgun-Sherki; Edward Hellriegel; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2019-03-14       Impact factor: 4.335

6.  Pharmacodynamic response profiles of anxiolytic and sedative drugs.

Authors:  Xia Chen; Freerk Broeyer; Marieke de Kam; Joke Baas; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2017-03-17       Impact factor: 4.335

7.  Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Authors:  Ricardo Alvarez-Jimenez; Geert Jan Groeneveld; Joop M A van Gerven; Sebastiaan C Goulooze; Anne Catrien Baakman; Justin L Hay; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2016-07-14       Impact factor: 4.335

8.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

9.  Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.

Authors:  Benjamin Berger; Sander Brooks; Rob Zuiker; Muriel Richard; Clemens Muehlan; Jasper Dingemanse
Journal:  CNS Drugs       Date:  2020-11-18       Impact factor: 5.749

10.  Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

Authors:  Erik T te Beek; Justin L Hay; Jonathan N Bullman; Clare Burgess; Kimberly J Nahon; Erica S Klaassen; Frank A Gray; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.